Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13995890 | 1.00 | ALDH1A1 (0.53) | ALDH1A1SIGMAR1IDO1ANPEPMAP4K4 | |
| SCHEMBL13995789 | 0.82 | ALDH1A1 (0.51) | ALDH1A1SIGMAR1IDO1ANPEPCYP2D6 | |
| SCHEMBL13995689 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SIGMAR1ANPEPKCNH2MEN1 | |
| SCHEMBL13995867 | 0.81 | ALDH1A1 (0.67) | ALDH1A1SIGMAR1ANPEPKCNH2MEN1 | |
| SCHEMBL12312577 | 0.79 | MAP4K4 (0.46) | SIGMAR1IDO1MAP4K4KCNH2 | |
| SCHEMBL17605317 | 0.73 | IDO1 (0.36) | ALDH1A1IDO1MAP4K4KCNH2TMEM97 | |
| SCHEMBL17605319 | 0.73 | IDO1 (0.36) | ALDH1A1IDO1MAP4K4KCNH2TMEM97 | |
| SCHEMBL13041031 | 0.72 | MAP4K4 (0.48) | ALDH1A1SIGMAR1IDO1MAP4K4MEN1 | |
| SCHEMBL13995594 | 0.72 | SIGMAR1 (0.74) | ALDH1A1SIGMAR1CYP2D6 | |
| SCHEMBL13995584 | 0.72 | SIGMAR1 (0.74) | ALDH1A1SIGMAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | ALDH1A1 3443/4885SIGMAR1 392/4885IDO1 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.